Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Guidance tracker
What ACUTAAS guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 02 Nov 2026 | Acutaas Chemicals filed the transcript of its Q2 FY27 earnings conference call held on October 27, 2026. Naresh Patel (CMD) said Q2 revenue was Rs 4,369 million, up 42.7% year-on-year, and guided FY27 revenue growth to around 30% (from 25%) and EBITDA margin to 38%-40%. Management said the CDMO revenue target of Rs... NSE copy | No results filed since | ||
| 27 Oct 2026 | Acutaas Chemicals filed its investor presentation on Q2 and H1 FY27 financial results (quarter and half year ended September 30, 2026) under Regulation 30 of the SEBI LODR Regulations. Q2 FY27 revenue from operations was ₹4,369 million, up 42.7% YoY; EBITDA was ₹1,760 million (40.3% margin, up 84.6% YoY); PAT was... NSE copy | No results filed since | ||
| 28 Jul 2026 | Acutaas Chemicals filed the transcript of its Q1 FY27 earnings conference call held on July 24, 2026, following results for the quarter ended June 30, 2026. Management reported revenue from operations of INR329.7 crores, up 59.1% Y-o-Y; EBITDA of INR113.1 crores at a 34.3% margin; and PAT of INR74.9 crores, up... NSE copy | +73.3 % | +42.7 % | -2.2 % |
| 24 Jul 2026 | Acutaas Chemicals filed its investor presentation on Q1 FY27 (quarter ended June 30, 2026) results under Regulation 30. Management (Mr. Naresh Patel, Executive Chairman and Managing Director) said revenue from operations grew 59.1% YoY to Rs. 3,297 mn, EBITDA rose 122.1% YoY to Rs. 1,131 mn, and PAT rose 70.4% YoY... NSE copy | +73.3 % | +42.7 % | -2.2 % |
| 06 May 2026 | Acutaas Chemicals filed the transcript of its Q4 FY26 earnings conference call held on April 30, 2026. Management said FY26 revenue from operations was INR1,339.4 crores (up 33% Y-o-Y), EBITDA INR480.4 crores (2x) and PAT a record INR356.4 crores; Q4 revenue was INR432.8 crores (up 40.3% Y-o-Y) and Q4 PAT INR134.3... NSE copy | +67.7 % | +59.1 % | +3.3 % |
| 30 Apr 2026 | Acutaas Chemicals filed its earnings investor presentation for Q4 and year ended March 31, 2026, under Regulation 30 of the SEBI LODR Regulations. Q4 FY26 revenue from operations was ₹4,328 million, up 40.3% YoY; EBITDA was ₹1,835 million (42.4% margin); PAT was ₹1,343 million (31.0% margin), up 114.1% YoY. FY26... NSE copy | +67.7 % | +59.1 % | +3.3 % |
| 03 Feb 2026 | Acutaas Chemicals filed the transcript of its Q3 FY26 earnings conference call held on January 28, 2026, following its results for the quarter and nine months ended December 31, 2025. Management said Q3 FY26 revenue from operations was INR393.2 crores, up 43% year-on-year, with PAT of INR106.2 crores (up 133.7%)... NSE copy | - | - | +3.2 % |
| 28 Jan 2026 | Acutaas Chemicals filed its investor presentation under Regulation 30 on the Q3 FY26 and nine-month results ended December 31, 2025. Q3 FY26 revenue from operations was ₹3,932 Mn, up 43.0% YoY; EBITDA was ₹1,507 Mn (38.3% margin, up 119.4% YoY); PAT was ₹1,062 Mn (27.0% margin, up 133.7% YoY). 9MFY26 revenue was... NSE copy | - | - | +3.2 % |
| 24 Oct 2025 | Acutaas Chemicals filed the transcript of its Q2 & H1 FY26 earnings conference call held on October 17, 2025. Management said Q2 FY26 revenue from operations grew 24.1% year-on-year to INR306.2 crores, with EBITDA of INR95.3 crores (31.1% margin) and PAT of INR71.9 crores, up 91.3%. For H1 FY26, revenue was... NSE copy | +140.2 % | +43.0 % | +3.8 % |
| 17 Oct 2025 | Acutaas Chemicals filed an investor presentation under Regulation 30 on financial results for the quarter and half year ended September 30, 2025 (Q2 FY26). Q2 FY26 revenue from operations was ₹3,062 million, up 24.1% YoY; EBITDA was ₹953 million (31.1% margin); PAT was ₹719 million (23.5% margin), up 91.3% YoY. H1... NSE copy | +140.2 % | +43.0 % | +3.8 % |
| 05 Aug 2025 | Acutaas Chemicals filed the transcript of its Q1 FY26 earnings conference call held on July 30, 2025. Management said Q1 FY26 revenue from operations grew 17.3% year-on-year to INR207 crores, with gross margin at 53.2% and EBITDA margin at 24.6%, and PAT of INR44 crores versus INR14.7 crores in Q1 FY25. Management... NSE copy | +93.5 % | +24.1 % | +7.1 % |
| 30 Jul 2025 | Acutaas Chemicals filed an investor/earnings presentation for the quarter ended June 30, 2025 (Q1 FY26) under Regulation 30 of SEBI LODR. Q1 FY26 revenue from operations was Rs 2,072 million, up 17.3% year-on-year; EBITDA was Rs 509 million (24.6% margin) and PAT was Rs 440 million (21.2% margin), per the P&L... NSE copy | +93.5 % | +24.1 % | +7.1 % |
| 08 May 2025 | Afi Ami Organics Limited filed the transcript of its Q4 FY25 earnings conference call held on May 2, 2025. Management said FY25 revenue from operations crossed INR1,006.9 crore (up 40.3% Y-o-Y), EBITDA was INR232.1 crore (up 80.6% Y-o-Y) and PAT was INR160.4 crore; Q4 FY25 revenue was INR308.5 crore (up 37.1%... NSE copy | +217.6 % | +17.3 % | +8.8 % |
| 02 May 2025 | Ami Organics Limited filed its investor presentation on Q4 and FY25 results (year ended March 31, 2025) under Regulation 30 of the SEBI LODR Regulations. FY25 revenue from operations grew 40.3% YoY to Rs 10,069 mn; EBITDA rose 80.6% to Rs 2,321 mn; PAT rose 98.6% to Rs 1,604 mn (PAT adjusted for exceptional items).... NSE copy | +217.6 % | +17.3 % | +8.8 % |
| 01 Feb 2025 | Afi Ami Organics Limited filed the transcript of its Q3 FY25 earnings conference call held on January 29, 2025, following Q3 and nine-month FY25 results. Management said Q3 FY25 revenue from operations was INR 275 crores, up 65.2% year-on-year and 11.5% sequentially, with EBITDA of INR 68.7 crores and PAT of INR... NSE copy | +217.6 % | +17.3 % | +8.8 % |
| 28 Jan 2025 | Investor presentation filed under Regulation 30 on Q3 and nine-month FY25 results (quarter and nine months ended December 31, 2024) of Ami Organics Limited. Q3FY25 revenue from operations grew 65.2% YoY to Rs. 2,750 mn; EBITDA Rs. 687 mn (25.0% margin); PAT Rs. 454 mn (16.5% margin). 9MFY25 revenue from operations... NSE copy | +168.3 % | +65.2 % | +4.4 % |
Filings tagged as guidance, newest first (16 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 24 Jul 2026 | Legal or regulatory | Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 on July 24, 2026, as recommended by the Audit Committee; statutory auditor M/s. Maheshwari & Co. issued a limited review report. Consolidated revenue from operations for Q1 FY27 was Rs... NSE copy |
| 30 Apr 2026 | Legal or regulatory | Board of Acutaas Chemicals Limited, at its meeting held on April 30, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with auditor's reports. Board recommended a final dividend of Rs. 2.5 per equity share of Rs. 5 each (50%) on 8,18,71,122... NSE copy |
| 04 Dec 2025 | Credit rating | Acutaas Chemicals Limited filed under Regulation 30 of SEBI Listing Regulations to intimate a credit rating action dated December 04, 2025. CARE Ratings Limited reaffirmed the long term / short term bank facilities rating at CARE A+; Stable / CARE A1+. The rated bank facilities amount was enhanced to Rs. 135.00... NSE copy |
| 08 May 2025 | Management change | Afi Ami Organics Limited filed the transcript of its Q4 FY25 earnings conference call held on May 2, 2025. Management said FY25 revenue from operations crossed INR1,006.9 crore (up 40.3% Y-o-Y), EBITDA was INR232.1 crore (up 80.6% Y-o-Y) and PAT was INR160.4 crore; Q4 FY25 revenue was INR308.5 crore (up 37.1%... NSE copy |
| 02 May 2025 | Management change | Ami Organics Limited filed its investor presentation on Q4 and FY25 results (year ended March 31, 2025) under Regulation 30 of the SEBI LODR Regulations. FY25 revenue from operations grew 40.3% YoY to Rs 10,069 mn; EBITDA rose 80.6% to Rs 2,321 mn; PAT rose 98.6% to Rs 1,604 mn (PAT adjusted for exceptional items).... NSE copy |
| 18 Dec 2024 | Credit rating | Ami Organics Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations on the credit rating for its bank facilities. CARE Ratings Limited upgraded the long term/short term bank facilities to CARE A+; Stable/CARE A1+ from CARE A; Stable/CARE A1, per its letter dated December 17, 2024. Rated... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (6 in all). A list of what was filed, not a judgement of the company.